Patents Assigned to Aqtual, Inc.
-
Patent number: 12258635Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.Type: GrantFiled: January 22, 2024Date of Patent: March 25, 2025Assignee: Aqtual, Inc.Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
-
Patent number: 12241127Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.Type: GrantFiled: January 22, 2024Date of Patent: March 4, 2025Assignee: Aqtual, Inc.Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
-
Patent number: 12241129Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.Type: GrantFiled: December 8, 2023Date of Patent: March 4, 2025Assignee: Aqtual, Inc.Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
-
Patent number: 12209288Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.Type: GrantFiled: July 21, 2023Date of Patent: January 28, 2025Assignee: Aqtual, Inc.Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
-
Patent number: 12195801Abstract: The present disclosure provides methods and systems for various uses of cell-free nucleic acid (cfNA). Functional typing of cfNA fragmentation patterns may be utilized in the non-invasive detection, diagnosis, and monitoring of disease. One embodiment may determine a stage of cancer in a subject, the progression of cancer in a subject, or the responsiveness to treatment of a cancer in a subject. Another embodiment disclosed herein may include sequencing-free diagnostic methods.Type: GrantFiled: January 22, 2024Date of Patent: January 14, 2025Assignee: Aqtual, Inc.Inventor: Diana Abdueva
-
Patent number: 12116632Abstract: The present disclosure provides methods and systems for various uses of cell-free nucleic acid (cfNA). Functional typing of cfNA fragmentation patterns may be utilized in the non-invasive detection, diagnosis, and monitoring of disease. One embodiment may determine a stage of cancer in a subject, the progression of cancer in a subject, or the responsiveness to treatment of a cancer in a subject. Another embodiment disclosed herein may include sequencing-free diagnostic methods.Type: GrantFiled: January 22, 2024Date of Patent: October 15, 2024Assignee: Aqtual, Inc.Inventor: Diana Abdueva
-
Patent number: 12018336Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.Type: GrantFiled: July 21, 2023Date of Patent: June 25, 2024Assignee: Aqtual, Inc.Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
-
Patent number: 11993818Abstract: The present disclosure provides methods and systems for various uses of cell-free nucleic acid (cfNA). Functional typing of cfNA fragmentation patterns may be utilized in the non-invasive detection, diagnosis, and monitoring of disease. One embodiment may determine a stage of cancer in a subject, the progression of cancer in a subject, or the responsiveness to treatment of a cancer in a subject. Another embodiment disclosed herein may include sequencing-free diagnostic methods.Type: GrantFiled: June 16, 2023Date of Patent: May 28, 2024Assignee: Aqtual, Inc.Inventor: Diana Abdueva
-
Patent number: 11965211Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.Type: GrantFiled: October 8, 2018Date of Patent: April 23, 2024Assignee: Aqtual, Inc.Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
